← CORT: big moves and long-term fundamentals中文

Corcept Therapeutics: The Long View

What the filings say about its story, dilution and cash runway.

Last updated Nov 16, 2026 · Reflects: 10-K for 2025 and the 10-Q for Q3 2026

This page is information, not investment advice.

1. In one paragraph

Last updated Nov 16, 2026. Reflects the 10-K for 2025 and the 10-Q for Q3 2026.

Corcept develops drugs that block the effects of the hormone cortisol and sells them in the US. Until 2026 it sold one medicine: Korlym (mifepristone) for hypercortisolism, also called Cushing’s syndrome. Since June 2024 it has also sold its own lower-priced authorized generic of Korlym (the same drug product sold without the Korlym brand name), after Teva launched a generic in January 2024. In 2025 revenue was $761.4M (+13%). Tablet volume rose 37%, but the average price fell 17.7% as more sales moved to the authorized generic. In March 2026 the FDA approved Lifyorli (relacorilant) with the chemotherapy nab-paclitaxel for platinum-resistant ovarian cancer (cancer that returns within six months of platinum-based chemotherapy), and by the third quarter it brought in more than a quarter of revenue. Corcept reports one segment (10-K 2025, 10-Q Q3 2026):

Revenue by product (disclosed; shares are our calculation1) 2025 Share 9M 2026 Share
Korlym and authorized generic (hypercortisolism) $761.4M 100% $622.6M 82%
Lifyorli (ovarian cancer; launched Apr 2026) — — $139.0M 18%
Total $761.4M $761.5M

2. Story so far

Last updated Nov 16, 2026. Reflects filings through Nov 3, 2026.

In short: For years Corcept lived on one drug, Korlym, and used the cash to buy back its own shares. A generic arrived in 2024, so the growth story moved to relacorilant, a newer molecule: approved for ovarian cancer as Lifyorli in 2026, it brought in $91.4M in its second quarter on sale. Its Cushing’s syndrome application was rejected once and is back under FDA review, with a decision due by Dec 17.

Date Milestone Source
Dec 15, 2021 Tender offer expires; Corcept repurchases 10.0M shares at $20.75 ($207.5M) 10-K 2022
Apr 5, 2023 Second tender offer: buys 6.6M shares at $22.00 ($145.4M) 10-K 2023
Dec 29, 2023 → Jan 2024 ★ A court rules that Teva’s generic Korlym does not infringe Corcept’s patents. Teva launches its generic in January; Corcept adds its own authorized generic in June 2024 10-K 2025
Jan 8, 2024 Board authorises a $200M share buyback 8-K
Dec 30, 2024 Files for FDA approval of relacorilant in Cushing’s syndrome 8-K
Mar 31, 2025 ★ Phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer meets its primary goal. The stock closes up 109%, from $54.63 to $114.22, per Yahoo Finance 8-K
Jul 31, 2025 → Nov 4, 2025 2025 revenue guide cut to $850–900M, then to $800–850M; Corcept cites capacity limits at its pharmacy vendor. Actual 2025 revenue: $761.4M Q2 2025 release, Q3 2025 release, Q4 2025 release
Oct 10, 2025 Gives notice ending its agreement with Optime Care, the specialty pharmacy that had dispensed Korlym since 2017 8-K
Dec 31, 2025 ★ Corcept announces that the FDA issued a “complete response letter” on Dec 30, declining to approve relacorilant for Cushing’s syndrome. The stock closes down 50%, from $70.20 to $34.80 (Yahoo Finance) 8-K
Jan 22, 2026 ROSELLA final results: 35% lower risk of death (median survival 16.0 vs 11.9 months) 8-K
Mar 25, 2026 ★ FDA approves Lifyorli, more than three months before its Jul 11 target action date 8-K
Jun 17, 2026 Resubmits the Cushing’s application; FDA decision due by Dec 17, 2026 8-K, Q2 2026 release
Jul 29, 2026 Q2: revenue $256.1M, including $47.6M from Lifyorli; 2026 guide raised to $1.1–1.2B. Stock +27% next day ($92.95 → $118.32, Yahoo Finance) Q2 2026 release
Oct 23, 2026 Start of our coverage: stock falls 20% after Genmab reports Phase 3 results for a rival ovarian cancer drug: Corcept falls 20% as a rival ovarian cancer drug aces its Phase 3 trial Genmab release, Yahoo Finance
Nov 3, 2026 Q3: revenue $340.5M, including $91.4M from Lifyorli; 2026 guide kept at $1.1–1.2B. Stock −12.6% over the next two days ($81.93 → $71.63, Yahoo Finance; our calculation2) Q3 2026 release

3. Latest quarter: did the story change?

Last updated Nov 16, 2026. Reflects Q3 2026 (quarter to Sep 30, released Nov 3).

Bottom line: Revenue rose a third from Q2 as Lifyorli nearly doubled and Korlym sales grew 19%, and profit almost tripled. Corcept kept its 2026 revenue guide rather than raising it; its low end implies fourth-quarter revenue slightly below the third’s (our calculation)3. In liver disease (MASH), miricorilant’s liver-fat reduction was not statistically significant against placebo.

Driver Last quarter → this quarter Management: before → now Signal
Total revenue Q2 $256.1M → Q3 $340.5M (+64% vs Q3 2025) 2026 revenue guide raised to $1.1–1.2B (Jul 29) → kept at $1.1–1.2B (Nov 3). Investing.com reported that the kept guide disappointed investors (reported, Investing.com) Better
Korlym and authorized generic $208.6M → $249.1M (+19%) “A record number of new prescriptions” (Jul 29) → awareness of diagnosing and treating Cushing’s syndrome “is steadily increasing” (Nov 3). Volume gave 75% of the rise vs Q3 2025; the rest came from an August 2025 price rise and better reimbursement (10-Q) Better
Lifyorli (ovarian cancer) $47.6M → $91.4M (+92%) Over 1,300 patients started (Jul 29) → more than 2,300 patients and more than 1,700 prescribing physicians since launch (Nov 3). No product guide Better
Profit Operating income $41.3M → $114.7M; net income $43.0M → $126.8M Back in profit in Q2 (Jul 29) → no profit guidance (Nov 3). Corcept expects 2026 research spending about the same as 2025’s (10-Q) Better
Miricorilant in MASH (liver disease) Results due by end of 2026 → MONARCH reported: the higher dose cut liver fat more than the lower dose, but the comparison with placebo was not statistically significant (10-Q) “Encouraged by the dose-dependent reductions in liver fat”; a Phase 2 trial of a higher dose will start “soon” (Nov 3) Watch

Sources: Q2 2026 release, Q3 2026 release, 10-Q Q3 2026. Corcept does not publish an adjusted (non-GAAP) profit measure.

Unresolved questions: whether the FDA approves relacorilant for Cushing’s syndrome by Dec 17; how much of the ovarian cancer market Lifyorli keeps if Genmab’s Rina-S is approved (Genmab has given no filing date; Genmab release) and alongside Merck’s pembrolizumab, approved for some of these patients in February 2026 (10-Q); whether the European Commission approves Lifyorli’s combination by the end of 2026.

4. Buybacks vs real dilution (5 years)

Last updated Nov 16, 2026. Reflects the equity statements in the 10-Ks for 2022 and 2025 and the 10-Q Q3 2026.

Dilution in one line: From Dec 31, 2020 to Dec 31, 2025 the share count fell 9.2%, about 1.9% a year compounded (our calculation)4. If you owned 1% of Corcept at the end of 2020, you’d own about 1.10% at the end of 2025 without buying more (our calculation)5. Buybacks more than offset the new shares from employee plans, about 119% of them (our calculation)6. Corcept has one class of common stock. Our scale: Net reduction (the share count fell).

Our rule of thumb: under 1% a year low, 1–3% moderate, over 3% high.

Change in shares outstanding, Dec 31, 2020 to Dec 31, 2025FY2021 −9.2%, FY2022 +1.8%, FY2023 −4.1%, FY2024 +1.7%, FY2025 +0.8%. Total −9.2% since Dec 31, 2020.−15%−10%−5%0%+5%FY2021: −9.2% in the period; −9.2% since Dec 31, 2020−9.2%FY2021FY2022: +1.8% in the period; −7.6% since Dec 31, 2020+1.8%FY2022FY2023: −4.1% in the period; −11.4% since Dec 31, 2020−4.1%FY2023FY2024: +1.7% in the period; −10.0% since Dec 31, 2020+1.7%FY2024FY2025: +0.8% in the period; −9.2% since Dec 31, 2020+0.8%FY2025−9.2%since Dec 31, 2020

Change in the period Total since Dec 31, 2020

Shares outstanding at period end (all classes): 116.7M on Dec 31, 2020, 106.0M on Dec 31, 2025, −9.2% (our calculation). A bar below zero means the count fell (net buybacks).

Dec 31, 2020 and Dec 31, 2025 counts from the author's bridge (10-K equity statements): 116.735M and 105.966M.

Period endShares outstandingChangeBuybacks (fiscal year)Stock-based pay (fiscal year)Stock pay as % of revenue
FY2025 (Dec 31, 2025)106.0M+0.8%$173M$85M11%
FY2024 (Dec 31, 2024)105.1M+1.7%$16M$61M9%
FY2023 (Dec 31, 2023)103.4M−4.1%$0$49M10%
FY2022 (Dec 31, 2022)107.8M+1.8%$0$42M11%
FY2021 (Dec 31, 2021)105.9M−9.2%—$43M12%
FY2020 (Dec 31, 2020)116.7M—$10M$34M9%

Shares outstanding from the balance sheets in the company's 10-K and 10-Q filings; buybacks (cash spent) and stock-based pay from its 10-Ks, via SEC EDGAR.

How we calculated this
Share bridge, Dec 31, 2020 → Dec 31, 2025 (our calculation from disclosed equity statements; millions) Shares
Start 116.7
+ Issued under employee plans (options exercised, restricted stock) +19.9
− Shares handed back by employees to cover option exercise costs and taxes −7.1
− Bought back in tender offers (2021, 2023) −16.6
− Bought back under buyback programmes (2021, 2024, 2025) −6.9
End 106.0 (−9.2%)
Shares issued for acquisitions, convertibles or offerings None in the period

Totals use unrounded filing figures; displayed components may not sum exactly because of rounding.

By Sep 30, 2026 the count had risen to 109.4M (+3.2% from Dec 31, 2025; our calculation7), as employee plans issued more shares than Corcept bought back: 52,000 shares for $5.7M in September (10-Q).

Prices paid and received:

Period Shares bought back Average price paid Spent Shares sold for cash Average price received Raised Sources
2021 13.87M $21.34 (our calculation) $296.0M — — — 10-K 2022 equity statement and note: tender offer 10.0M at $20.75 ($207.5M); programme 3.87M for $88.5M ($22.88, our calculation)
2022 — — — — — — 10-K 2022 equity statement
2023 6.61M $22.00 (tender price) $145.4M — — — 10-K 2023 note; 10-K 2025 equity statement
2024 0.49M $32.23 (our calculation) $15.7M — — — 10-K 2025 equity statement: 486K shares, $15.664M
2025 2.59M $66.71 (our calculation) $172.9M — — — 10-K 2025 equity statement: 2,592K shares, $172.915M
2026 to Sep 30 0.05M $109.75 $5.7M — — — 10-Q Q3 2026: 52K shares in September, $5.745M

Corcept bought back shares in 2021, 2023, 2024 and 2025, at average prices that rose from about $21 to about $67 a share, and a few in September 2026 at about $110. It sold no shares for cash through offerings or at-the-market programmes in the period; employee-plan proceeds are excluded. Average price paid is derived (our calculation)8.

Basis and details
  • Figures exclude the federal excise tax on buybacks. Corcept has not split its stock, so all figures are as reported.
  • Buybacks exclude shares employees hand back to cover option exercise costs and taxes (7.1M shares in 2021–25), which Corcept reports on a separate line from its buyback programme.
  • Corcept sold no shares for cash through offerings or at-the-market programmes in 2021 through Sep 30, 2026; employee option and stock-purchase-plan proceeds are excluded.
  • For reference, the stock closed at $72.94 on Nov 13, 2026 (Yahoo Finance).
Diluted shares and stock pay (disclosed; % is our calculation) 2021 2022 2023 2024 2025 9M 2026
Weighted diluted shares (M) 126.0 116.0 111.7 113.5 120.0 119.4
Stock-based pay ($M) 42.9 42.4 48.9 61.4 84.5 81.9
Stock pay as % of revenue9 12% 11% 10% 9% 11% 11%

Over 2021–25 Corcept spent more on buybacks than stock pay cost it: $630.0M against $280.2M (our calculation)10.

Share-count details
  • Diluted shares include options: in Q3 2026 they were 123.2M against 106.6M basic (10-Q).
  • As of Sep 30, 2026, $5.7M remained under the January 2024 buyback authorisation, which has no expiry date (10-Q).
  • In Q3 2026 employees also handed back 556,000 shares, worth $61.9M, to cover option exercise costs and taxes (10-Q). The Q3 release’s “$43.7 million” of stock acquired combines buybacks and these cash tax payments (our reading of the cash-flow statement).

5. Profit vs cash (latest FY and TTM)

Last updated Nov 16, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026. TTM = the four quarters to Sep 30, 2026 (our calculation)11.

Corcept’s operating cash flow has run above its net income, mainly because stock pay is a non-cash expense. Corcept publishes no adjusted profit measure, so there is no company reconciliation to show. With Lifyorli selling, profit and cash flow in the past four quarters were well above 2025’s, even though growing sales left more money waiting to be collected.

$M 2025 (disclosed unless marked otherwise) TTM (our calculation)
Revenue 761.4 963.6
Net income 99.7 162.3
Adjusted profit measure None published None published
Operating cash flow 142.0 198.1
Capital spending 0.2 3.5
Free cash flow (our calculation)12 141.8 194.6

The biggest items between profit and cash, grouped by what they mean for future profit and cash:

Helps future profit or cash:

  • Receivables took $5.8M in 2025 and $51.3M in the first nine months of 2026 as sales grew: Receivables reflect sales already in profit, awaiting collection; the cash arrives if and when customers pay.

Hurts future profit or cash:

  • Stock pay added back $84.5M in 2025 ($102.7M TTM): Not a cash cost in operations, but Corcept paid $72.9M in 2025 ($91.7M TTM) to cover employees’ taxes on shares it held back. That is a financing cash flow, so it is not in free cash flow.

One-off / no lasting effect:

  • Deferred taxes reduced operating cash flow by $37.5M in 2025 ($15.8M TTM): Booked tax benefits that bring no cash in the period: timing between profit and cash.
  • Unpaid bills to suppliers added $25.1M in 2025 but took away $18.5M in the first nine months of 2026: Timing: the bills were paid down.
The raw reconciling items
  • Stock pay added back $84.5M in 2025 ($102.7M TTM). The related cash cost shows up elsewhere: Corcept paid $72.9M in 2025 ($91.7M TTM) to cover employees’ taxes on shares it held back. That is a financing cash flow, so it is not in free cash flow.
  • Deferred taxes reduced operating cash flow by $37.5M in 2025 ($15.8M TTM): booked tax benefits that bring no cash in the period.
  • Unpaid bills to suppliers added $25.1M in 2025 but took away $18.5M in the first nine months of 2026 as they were paid down.
  • Receivables took $5.8M in 2025 and $51.3M in the first nine months of 2026 as sales grew.
  • Accrued and other liabilities, which include amounts set aside for rebates and other costs not yet paid, added $3.9M in 2025 and $36.1M in the first nine months of 2026.
Self-funding

Funding: how long without new money? (our calculation, as of Sep 30, 2026)

  • Self-funding: $194.6M of free cash flow in the 12 months to Sep 30, 2026; no debt, and $662.3M of cash and securities13.
Funding details
  • Cash, cash equivalents and marketable securities: $662.3M (10-Q).
  • Debt and convertible notes due within 24 months: none; the Sep 30 balance sheet shows no borrowings.
  • Undrawn credit lines: none disclosed.
  • At-the-market share-sale programme: none disclosed.
  • Based on past cash flow; spending plans can change it.

Extends the runway:

  • None (no undrawn credit lines or at-the-market programme disclosed).

Shortens the runway:

  • None (no debt, maturities or minimum-cash covenants disclosed).

Conditional:

  • None.

6. Customer and contract exposure

Last updated Nov 16, 2026. Reflects the 10-K 2025 and the 10-Q Q3 2026.

Korlym sales run through one specialty pharmacy, Curant Health, which collects the insurer payments behind more than 99% of hypercortisolism revenue; Corcept can end the agreement on 180 days’ notice. Most revenue still comes from one product family that already faces a generic, and lawsuits over how Corcept defended it are heading for a hearing in December and a trial in March 2027.

Pharmacy, distributor and pricing details
  • Curant Health, Corcept’s specialty pharmacy since 2025, dispenses Korlym and the authorized generic. It collects the insurer payments behind more than 99% of hypercortisolism revenue. Curant never owns the drug; title passes from Corcept straight to the patient. Disclosed.
  • The Curant agreement (June 2025) runs to June 2028, then renews one year at a time. Corcept can end it on 180 days’ notice. Disclosed.
  • Optime Care was the exclusive pharmacy from 2017 to 2025. Corcept said its previous vendor could not fully meet demand in 2025 and that it completed the move to Curant in Q1 2026 (10-Q); the Optime agreement ended Jan 8, 2026 (8-K). Since Q3 the 10-Q’s summary of risks names “the inability of our specialty pharmacy vendors to meet demand”.
  • Sales to a specialty distributor were less than 1% of revenue in each of 2023–25. Lifyorli goes through a specialty pharmacy and specialty distributors, which sell to cancer practices, purchasing groups and hospitals; the filings give no customer percentages for it. Disclosed.
  • Medicare and Medicaid get rebates on Corcept’s drugs. A Medicare pricing proposal from December 2025 (GUARD) would add rebates for Part D drugs such as Lifyorli from 2027. Corcept says its participation would likely be mandatory; a final rule has been under review at the Office of Management and Budget since June 2026. In September 2026 Medicare finalised a similar model (GLOBE) for Part B drugs; Corcept says it remains to be seen whether such initiatives will apply to its products (10-Q).
Key contract or dispute Date Status Note
Teva generic Korlym (patent case) Generic launched Jan 2024 Appeals court affirmed non-infringement Feb 19, 2026; rehearing denied Jul 10, 2026. Corcept intends to ask the Supreme Court to hear the case Korlym method-of-use patents run 2028–2038 (8-K, 10-Q)
Teva antitrust suit against Corcept and Optime Filed Jun 2024 Hearing on Corcept’s motion for summary judgment Dec 16, 2026; trial scheduled for March 2027 Insurers Aetna, Health Care Service Corp., Humana and Molina filed a similar suit in February 2025 in state court, which refused to pause it in July 2026; no trial date set (10-Q)
Whistleblower suit (False Claims Act) over Korlym sales Filed 2017 DOJ declined to intervene in May 2026; the former employee who filed it is pursuing it alone. Corcept moved to dismiss it in September 2026 8-K, 10-Q
Shareholder class action and derivative suit over statements about the Cushing’s application Filed Feb and Apr 2026 Amended class-action complaint filed Aug 28, 2026; the derivative suit is paused until the court rules on Corcept’s expected motion to dismiss 10-Q

7. Corcept’s strategy for long-term growth

Last updated Nov 16, 2026. Reflects the 10-K for 2025, the 10-Q for Q3 2026 and the Q3 release (Nov 3, 2026).

Corcept is trying to turn one idea, blocking the effects of cortisol, into several businesses: a larger Cushing’s syndrome franchise, Lifyorli in more cancers, and new uses in liver disease and amyotrophic lateral sclerosis (ALS). So far the ovarian cancer launch is the part with sales to show.

  • Pressures on the core business:
    • Korlym has faced Teva’s generic since January 2024, which Corcept says “has materially reduced the price we receive”; Sun and Hikma have settlements that let them sell generics if the FDA approves their products and Teva’s stays on the market. The courts found that Teva’s generic does not infringe Corcept’s patents (10-Q).
    • Other approved Cushing’s drugs include Recordati’s osilodrostat and Xeris’s levoketoconazole (10-Q).
    • In platinum-resistant ovarian cancer, Merck’s pembrolizumab and Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan are approved for subsets of patients (10-Q), and Genmab reported Phase 3 results for Rina-S in October (Genmab release).
    • Who pays and who sets the rules: Korlym’s price is under attack in court from a rival (Teva) and from large insurers (Aetna, Health Care Service Corp., Humana and Molina), who make similar allegations; Corcept is defending both cases (section 6). Medicare’s proposed GUARD rebates could cut Lifyorli’s Medicare price, and Corcept lists public perception of mifepristone, also used to end early pregnancies, and laws limiting it as a risk to Korlym sales (10-Q).
  • The strategy in management’s words (GR is the glucocorticoid receptor, through which cortisol acts; antagonism means blocking it): “Our goal is to establish GR antagonism as a mechanism for treating a broad range of solid tumors, in combination with a variety of anticancer therapies, at every stage of disease”, and “we are aggressively expanding our research activities” (Bill Guyer, Chief Development Officer, Q3 release). The steps so far:
    • Cushing’s syndrome: relacorilant’s application was resubmitted in June after the FDA asked for further analyses of existing data; a decision is due by Dec 17, 2026. If approved, its orphan designation would give seven years of US market exclusivity in hypercortisolism. Corcept is also pushing screening: an October 2026 diabetes consensus report (ADA and EASD) recommends screening some patients with poorly controlled diabetes for hypercortisolism and cites mifepristone (Q3 release, 10-Q);
    • cancer: Lifyorli is in the National Comprehensive Cancer Network (NCCN) treatment guidelines as a preferred regimen since April 2026, and the EU’s medicines committee recommended approval in September. Phase 2 trials test it in ovarian cancer that progressed on PARP inhibitors, drugs that block a DNA-repair enzyme (BELLA Part B), endometrial (Part C), pancreatic (TRIDENT), cervical (STELLA) and prostate cancer, and a second molecule, nenocorilant, with immunotherapy (SYNERGY);
    • liver disease (MASH): MONARCH’s results for miricorilant were not statistically significant against placebo; Corcept plans a new Phase 2 trial at a higher daily dose;
    • amyotrophic lateral sclerosis (ALS), a progressive neuromuscular disease: after exploratory analyses of its Phase 2 DAZALS trial, Corcept plans a Phase 3 trial of dazucorilant in 2027;
    • deals: Corcept licenses some patents from the University of Chicago, on which it owes royalties (10-K 2025); the filings we reviewed describe no acquisitions, and surplus cash has gone to buybacks and tender offers ($630.0M in 2021–25, section 4).
  • How well it is working, in numbers:
    • Lifyorli: $139.0M of net revenue in its first two quarters on sale, more than 2,300 patients treated and more than 1,700 prescribing physicians (Q3 release);
    • Korlym and the authorized generic: $622.6M in the first nine months of 2026, +11% (our calculation14), mostly from more tablets sold (10-Q);
    • BELLA Part A, in 95 women with platinum-resistant ovarian cancer: median progression-free survival (time alive without the cancer worsening) of 7.2 months, and tumours shrank or disappeared in 59% of patients with Lifyorli, nab-paclitaxel and bevacizumab; the trial had no comparison group (Q3 release);
    • targets: 2026 revenue of $1.1–1.2B; Corcept has given no product-level or longer-term targets.
  • What to watch: see section 8.

8. What to watch

Last updated Nov 16, 2026. Reflects the 10-Q for Q3 2026 and the Q3 2026 release (Nov 3, 2026).

Date Item Source
Dec 16, 2026 Court hearing on Corcept’s motion for summary judgment in the Teva antitrust case 10-Q
Dec 17, 2026 FDA target action date for its decision on relacorilant in Cushing’s syndrome Q3 2026 release
By end of 2026 (expected) The European Commission’s final decision on relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer, after the European Medicines Agency’s human medicines committee recommended approval in September Q3 2026 release, Corcept release
Mar 2027 The Teva antitrust case is scheduled for trial 10-Q
2027 (planned) Start of a Phase 3 trial of dazucorilant in ALS Q3 2026 release
By end of 2027 (expected) Results from BELLA Parts B and C, TRIDENT (pancreatic cancer), the prostate cancer trial and SYNERGY Q3 2026 release
Not announced Q4 and full-year 2026 results; Corcept had not announced a date as of Nov 16, 2026 Corcept investor relations
Additional dates
Date Item Source
“Soon” (no date) Start of a Phase 2 trial of miricorilant at 100 mg daily in MASH Q3 2026 release
Date not set Corcept’s petition asking the Supreme Court to hear the Teva patent case 10-Q
Date not set Genmab’s full Rina-S data and filing plans Genmab release

Valuation at each update

At the close used for each update, from the filings available then. Frozen when the update is published; never revised.

UpdateCloseMarket valueEVP/SEV/salesP/EP/FCFRevenue growthFCF marginNet cash (debt)Basis
Oct 27, 2026$85.86 (Oct 23)$9.1B$8.6B11.0×10.3×167.6×*85.1×+16%13%$545M12 months to Jun 30, 2026
Nov 16, 2026$72.94 (Nov 13)$8.0B$7.3B8.3×7.6×50.1×41.0×+30%20%$662M12 months to Sep 30, 2026

Our calculation from each update's filings (latest at the newest update: 10-Q for the quarter to Sep 30, 2026, filed Nov 3, 2026); not investment advice. n/m = not meaningful (e.g. negative earnings). Hover a heading for its definition. Oct 27, 2026: * Trailing P/E includes a $29M income-tax benefit in the 12 months to Jun 30, 2026. Oct 27, 2026 row: Updated Nov 16, 2026: cash and investments now include Corcept's long-term marketable debt securities, as in its filings: $544.6M (was $308.2M); net cash and enterprise value recomputed. Price, date and market value are unchanged. Nov 16, 2026 price: official close, Yahoo Finance, CNBC.

Notes and calculations

  1. Korlym and generic 622.553 ÷ 761.522 = 82%; Lifyorli 138.969 ÷ 761.522 = 18% (first nine months of 2026, $M). ↩

  2. 71.63 ÷ 81.93 − 1 (closes of Nov 5 and Nov 3, 2026). ↩

  3. Low end of the 2026 guide $1,100M − nine-month revenue $761.5M = $338.5M, against $340.5M in Q3. ↩

  4. Change = 105.966 ÷ 116.735 − 1; annual rate = (105.966 ÷ 116.735)^(1/5) − 1. ↩

  5. 1% × 116.7M ÷ 106.0M. ↩

  6. Shares bought back ÷ shares issued under employee plans = 23.6M ÷ 19.9M (23.555 ÷ 19.853). ↩

  7. 109.365 ÷ 105.966 − 1 (millions of shares, Sep 30, 2026 vs Dec 31, 2025). ↩

  8. $ spent ÷ shares bought back. ↩

  9. Stock pay ÷ revenue. ↩

  10. Sums of the yearly figures. ↩

  11. 2025 + first nine months of 2026 − first nine months of 2025. ↩

  12. Operating cash flow − capital spending. ↩

  13. $98.7M cash + $272.0M short-term + $291.6M long-term marketable securities. ↩

  14. 622.553 ÷ 559.282 − 1 (first nine months of 2026 vs 2025, $M). ↩

Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.

About Corcept Therapeutics: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)